Restaysis (ciclosporin)
- Region
- 🇪🇺 EU
- Active substance
- ciclosporin
- Company
- Allergan Pharmaceuticals International Limited
- Status
- Application withdrawn
- Therapeutic area
- Dry Eye Syndromes
- Application
- EMEA/H/C/004229
- ATC
- S01XA18
- Official record
- www.ema.europa.eu
Indication
For the treatment of moderate dry eye disease in adults.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Ikervis Authorised · Santen Oy
- 🇪🇺 Verkazia Authorised · Santen Oy
- 🇪🇺 Vevizye Authorised · Laboratoires Théa
- 🇪🇺 Vekacia Application withdrawn · Novagali Pharma S.A.
Follow Restaysis
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.